Related Experiment Video
Updated: Aug 13, 2026
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
[Clinical studies on cefmenoxime in pediatric field]
Insights
Cefmenoxime (CMX), a novel cephalosporin antibiotic, demonstrated significant clinical efficacy in treating moderate to severe pediatric infections. Bacterial eradication and positive clinical responses were observed with no significant adverse effects in young patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Background:
- Pediatric infections necessitate effective and safe antimicrobial agents.
- Cephalosporins are a critical class of antibiotics used in treating bacterial infections.
- Evaluating new antibiotics like cefmenoxime (CMX) is essential for expanding treatment options.
Observation:
- This study assessed the clinical effectiveness of cefmenoxime (CMX) in 22 pediatric patients (5 days to 8 years) with moderate to severe infections.
- Patients presented with diverse infections including bronchitis, pneumonia, sepsis, meningitis, and urinary tract infections.
- Cefmenoxime was administered intravenously, 4 times daily, at doses ranging from 40 to 200 mg/kg/day for approximately 3 to 15 days.
Findings:
- Cefmenoxime showed clinical effectiveness in all evaluable cases, with excellent, good, or fair responses in 17 out of 22 patients.
- Bacterial eradication was achieved for all 6 isolated causative bacterial strains, including S. pneumoniae, H. influenzae, E. coli, and K. pneumoniae.
- No notable adverse side effects were reported during the treatment period, indicating a favorable safety profile.
Implications:
- Cefmenoxime (CMX) presents a promising therapeutic option for managing serious pediatric bacterial infections.
- The antibiotic's efficacy and safety profile warrant further investigation in larger pediatric populations.
- This study contributes to the evidence base for using novel cephalosporins in pediatric infectious disease management.
Abstract:
A new cephalosporin antibiotic, cefmenoxime (CMX) was administered to 22 patients aged 5 days to 8 years, and who had moderate or severe pediatric infections, to examine its clinical effect. The infections were 3 of acute bronchitis, 2 cases of asthmatic bronchitis, 6 of acute pneumonia, 1 of Mycoplasma pneumonia, 2 of sepsis (1 accompanied with pneumonia), 3 of vacterial meningitis, 2 of urinary tract infection, 1 of acute appendicitis, 1 of aseptic meningitis and 1 of fever of undetermined origin. The drug was administered by one shot intravenous injection 4 times daily at the dose of 40 approximately 200 mg/kg/day. The drug was administered for 3 approximately 15 days, the total dosage administered being 0.7 approximately 43.5 g. Clinically, excellent, good and fair response was obtained in 2, 11 and 4 cases, respectively, the drug being effective in all cases excluding the 5 cases in which judgement was unknown. The 6 strains of bacteria isolated from the lesion as the assumed causative bacteria (1 strain of S. pneumoniae, 2 of H. influenzae, 2 of E. coli, 1 of K. pneumoniae) were all eradicated after drug administration. No notable side effects were produced.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:26Urine Studies II: Urine Culture and Sensitivity Test
01:25Mechanism of Antibiotic Resistance in MRSA
01:25Clinical Significance of Antibiotic Resistance